Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the AutoImmunity and...

Area of Science:

• Rheumatology
• Immunology
• Clinical Medicine

Background:

• Rheumatoid arthritis (RA) patients can develop systemic rheumatoid vasculitis (SRV).
• Rituximab is an established therapy for RA and antineutrophil cytoplasmic antibody-associated vasculitis.
• The efficacy of rituximab in SRV requires further real-world investigation.

Purpose of the Study:

• To assess the real-world efficacy and safety of rituximab for treating active SRV.
• To evaluate treatment outcomes including remission rates and changes in corticosteroid dosage.

Main Methods:

• Analysis of data from the AutoImmunity and Rituximab registry.
• Inclusion of 17 RA patients treated with rituximab for active SRV.
• Assessment of disease activity using Birmingham Vasculitis Activity Score (BVAS/RA) and prednisone dosage.

Main Results:

• 71% of patients achieved complete remission at 6 months, with BVAS/RA decreasing from 9.6 to 0.6.
• 82% achieved sustained remission at 12 months; prednisone dosage significantly reduced.
• Severe infections occurred at a rate of 6.4 per 100 patient-years; maintenance therapy prevented relapses.

Conclusions:

• Rituximab is effective for inducing remission in SRV in a clinical setting.
• Significant reduction in prednisone use and acceptable safety profile observed.
• Maintenance therapy with rituximab appears necessary for sustained SRV remission.